A1 Adenosine Receptor Upregulation and Activation Attenuates Neuroinflammation and Demyelination in a Model of Multiple Sclerosis

Journal of Neuroscience

Volumn 24, Issue 6, 2004, Pages 1521-1529

  Tsutsui, Shigeki ^a   Schnermann, Jurgen ^b   Noorbakhsh, Farshid ^a   Henry, Scot ^a   Yong, V Wee ^a   Winston, Brent W ^a   Warren, Kenneth ^c   Power, Christopher ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adenosine amine congener; Caffeine; Cytokines; Demyelination; EAE; MMPs

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE DERIVATIVE; CAFFEINE; CYTOKINE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1BETA; MACROPHAGE ELASTASE;

ALLERGIC ENCEPHALITIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; CONTROLLED STUDY; CYTOTOXICITY; DEMYELINATION; DISEASE MODEL; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNITY; MACROPHAGE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; UPREGULATION;

ADENOSINE; ANIMALS; CAFFEINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; MACROPHAGES; MATRIX METALLOPROTEINASE 12; METALLOENDOPEPTIDASES; MICE; MICE, KNOCKOUT; MICROGLIA; MULTIPLE SCLEROSIS; MYELIN SHEATH; PHENOTYPE; RECEPTOR, ADENOSINE A1; RECURRENCE; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SPINAL CORD; UP-REGULATION;

EID: 1242336753     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4271-03.2004     Document Type: Article

References (53)

1. Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, Koprowski H (1995) Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA 92:12041-12045.
2. Bansal R, Warrington AE, Gard AL, Ranscht B, Pfeiffer SE (1989) Multiple and novel specificities of monoclonal antibodies O1, O4, and R-mAb used in the analysis of oligodendrocyte development. J Neurosci Res 24:548-557.
3. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, Oksenberg JR (2000) Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 165:6576-6582.
4. Bar-Or A, Oliveira EM, Anderson DE, Hafler DA (1999) Molecular pathogenesis of multiple sclerosis. J Neuroimmunol 100:252-259.
5. Bauer J, Huitinga I, Zhao W, Lassmann H, Hickey WF, Dijkstra CD (1995) The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 15:437-446.
6. Bona E, Aden U, Fredholm BB, Hagberg H (1995) The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. Pediatr Res 38:312-318.
7. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153:4159-4168.
8. Boven LA, Vergnolle N, Henry SD, Silva C, Imai Y, Holden J, Warren K, Hollenberg MD, Power C (2003) Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol 170:2638-2646.
9. Boyle DL, Sajjadi FG, Firestein GS (1996) Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 39:923-930.
10. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-1308.
11. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC, Adams SE, Gearing AJ (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72:155-161.
12. Chou CC, Vickroy TW (2003) Antagonism of adenosine receptors by caffeine and caffeine metabolites in equine forebrain tissues. Am J Vet Res 64:216-224.
13. Cronstein BN (1994) Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76:5-13.
14. Dall'Igna OP, Porciuncula LO, Souza DO, Cunha RA, Lara DR (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138:1207-1209.
15. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469-1477.
16. Fozard JR, McCarthy C (2002) Adenosine receptor ligands as potential therapeutics in asthma. Curr Opin Investig Drugs 3:69-77.
17. Gillson G, Richard TL, Smith RB, Wright JV (2002) A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Mult Scler 8:30-35.
18. Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM, Fredholm BB, Tobena A, Pekny M, Johansson B (2002) Mice lacking the adenosine Al receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 16:547-550.
19. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES (1996) Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 157:4634-4640.
20. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S (1996) A novel gene ibal in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 224:855-862.
21. Jacobson KA, Zimmet J, Schulick R, Barone S, Daly JW, Kirk KL (1987) Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors. FEBS Lett 225:97-102.
22. Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB (1996) Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 17:108-113.
23. Johnston JB, Silva C, Gonzalez G, Holden J, Warren KG, Metz LM, Power C (2001a) Diminished adenosine Al receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 49:650-658.
24. Johnston JB, Silva C, Holden J, Warren KG, Clark AW, Power C (2001b) Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann Neurol 50:434-442.
25. Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7:115-121.
26. Le Moine O, Stordeur P, Schandene L, Marchant A, de Groote D, Goldman M, Deviere J (1996) Adenosine enhances IL-10 secretion by human monocytes. J Immunol 156:4408-4414.
27. Linden J (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41:775-787.
28. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R (2002) CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8:620-624.
29. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78-83.
30. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717.
31. Mayne M, Shepel PN, Jiang Y, Geiger JD, Power C (1999) Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol 45:633-639.
32. Miller SD, Shevach EM (1998) Immunoregulation of experimental autoimmune encephalomyelitis: editorial overview. Res Immunol 149:753-759.
33. Navikas V, Link H (1996) Cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 45:322-333.
34. Neuhaus O, Archelos JJ, Hartung HP (2003) Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24:131-138.
35. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW (1999) Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464-8475.
36. Olah ME, Stiles GL (1995) Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581-606.
37. Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305-312.
38. Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y, Yong VW, Peeling J (2003) Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 53:731-741.
39. Ren H, Stiles GL (1994) Posttranscriptional mRNA processing as a mechanism for regulation of human A1 adenosine receptor expression. Proc Natl Acad Sci USA 91:4864-4866.
40. Ren H, Stiles GL (1995) Separate promoters in the human A1 adenosine receptor gene direct the synthesis of distinct messenger RNAs that regulate receptor abundance. Mol Pharmacol 48:975-980.
41. Ren H, Stiles GL (1999) Dexamethasone stimulates human A1 adenosine receptor (AIAR) gene expression through multiple regulatory sites in promoter B. Mol Pharmacol 55:309-316.
42. Ribeiro JA, Sebastiao AM, de Mendonca A (2002) Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 68:377-392.
43. Riches DW, Underwood GA (1991) Expression of interferon-beta during the triggering phase of macrophage cytocidal activation: evidence for an autocrine/paracrine role in the regulation of this state. J Biol Chem 266:24785-24792.
44. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS (1996) Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 156:3435-3442.
45. Schwaninger M, Neher M, Viegas E, Schneider A, Spranger M (1997) Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. J Neurochem 69:1145-1150.
46. Shi D, Nikodijevic O, Jacobson KA, Daly JW (1993) Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol 13:247-261.
47. Sommer I, Schachner M (1981) Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: an immunocytological study in the central nervous system. Dev Biol 83:311-327.
48. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103:807-815.
49. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, Schnermann J (2001) Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 98:9983-9988.
50. Svenningsson P, Fredholm BB (1997) Glucocorticoids regulate the expression of adenosine A1 but not A(2A) receptors in rat brain. J Pharmacol Exp Ther 280:1094-1101.
51. Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE (2003) Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol 138:106-114.
52. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75-80.
53. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, Clark-Lewis I, Overall CM, Power C (2003) HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 6:1064-1071.